DILAWAR AJANI, MD

Internal Medicine Specialist
dajani@synergygroupus.com

AFFILIATED ADDRESSES

Synergy Groups Medical LLC
8121 Broadway Street, Suite 120 Houston, TX 77061
3281 Rocky Creek Dr. Ste. 500 Missouri City, TX 77459
10101 Harwin Dr, Suite 395 Houston, TX 77036

EDUCATION

Residency-Internal Medicine – 1991
University of Texas, TX – USA

Internship-Internal Medicine – 1990
V.A. Medical Center, PA – USA

Internship-Internal Medicine – 1989
University of Sindh -Liaquat Medical College, Sindh– Pakistan

Doctor of Medicine
University of Sindh -Liaquat Medical College, Sindh– Pakistan

LICENSE

1. **Medical License, State of Texas- J2439**
2. **Drug Enforcement Agency – Registration #FA6869157**
3. **NPI #**1528047115

BOARD CERTIFICATION

- American Board of Medicine, ***Board Eligible*** – Internal Medicine since 1992

TRAINING

- Collaborative Institutional Training Initiative (CITI) Good Clinical Practice (Current)
- The National Institutes of Health (NIH): Completed 27 Sep 2018
- EDC(Current)
- Virtual Trial Capable Certified (Current)

LANGUAGE

1. Fluent in English
2. Fluent in Hindi
3. Fluent in Urdu
4. Fluent in Gujrati

EXPERIENCE:

Principal/Sub-Investigator — Dec 2016 - Present
Synergy groups Medical LLC
*(Previously Known as **Discovery MM Services, Inc**.)*

Physician — 2015-Present
Katy Wellness Center, TX

Principal/Sub-Investigator — 2015-2016
Gulf Coast Medical Research, TX

Principal/Sub-Investigator — 2000-2015
Southwest Clinical Trial, TX

Physician Associates — 1992-Present
Southwest Memorial Hospital, TX

RESEARCH:

- A Phase III, Multicenter, Randomized, Double-Blind Study to Assess Cardiovascular Outcomes Following Treatment with XXXX In Subjects with Type 2 Diabetes Mellitus and Established Vascular Disease.
- A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of XXXX Vs Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control.
- A Multicenter, International Randomized, Parallel Group, Double-Blind, Placebo-Controlled Cardiovascular Safety & Renal Microvascular Outcome with XXXX XXmg Once Daily in Patient w/ T2DM at High Vascular Risk
- An open Label, Randomized, Parallel- group, three treatment arm, multicenter study on Hypogonadal males to evaluate the effect on 24-hour ambulatory blood pressure after 16-week continuous treatment with marketed testosterone products
- Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/ indapamide) compared to placebo for the treatment of hypertension: An international, multi center, randomized, double-blind, placebo controlled, parallel group trial

- A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (>70 mg/dl) despite receiving maximally tolerated statin therapy (VICTORION- INITIATE)

- A Global Registry on Long Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation Phase II/ III.

- A Phase III Multicenter, International, Randomized, Parallel Group, Double-Blind Cardiovascular Safety of XXXX (XXmg And XXmg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients with Increased Cardiovascular Risk

- A Randomized, Double Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy, Safety, And Tolerability of XXXX In the Treatment of Patients with Diarrhea- Predominant Irritable Bowel Syndrome.

- A Randomized, Double Blind, Placebo-Controlled, Multicenter Trial with An Enriched Study Design to Assess the Efficacy And Safety Of XXXXX/XXXXX Controlled-Release Tablets (XXX) Compared To Placebo In Opioid-Experienced Subjects with Moderate To Severe Pain Due To Chronic Low Back Pain Who Require Around the Clock Opioid Therapy.

- A Prospective, Randomized, Double-Blind Comparison of Long-Acting Basal Insulin Analog XXXX to Lantus in Adults' Patients with Type 2 Diabetes Mellitus

- An Observational Study, A Cross-Sectional Evaluation of Type 2 Diabetes and Associated Chronic Kidney Disease in the Primary Care Setting.

- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety And Efficacy Of XXXX In Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension Treated With An Angiotensin-Converting Enzyme Inhibitor (ACEI) Or Angiotensin Receptor Blocker (ARB) And An Additional Antihypertensive Medication.

- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of XXXX In Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on An Angiotensin-Converting Enzyme Inhibitor (ACEI) Or Angiotensin Receptor Blocker (ARB).

- A Randomized, Double-Blind Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study to Evaluate Efficacy, Safety, And Tolerability of XXXX In the Treatment of Patients with Irritable Bowel Syndrome with Diarrhea.

- A 24-Week, Multicenter, Randomized, Double-Blind, Age-Stratified, Placebo Controlled Phase III Study With A 28-Week Extension Period To Evaluate The Efficacy And Safety Of XXX XX mg Once Daily In Patients With Type 2 Diabetes, Cardiovascular Disease And Hypertension, Who Exhibit Inadequate Glycemic Control On Usual Care.

- A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of XXXX As Compared with XXX In Subjects with Type 2 Diabetes Mellitus with Renal Impairment

- A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of XXXX As Compared with XXX In Subjects with Type 2 Diabetes Mellitus.

- A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of XXXX Administered in Combination with Insulin XXX as Compared with The Combination of Insulin XX and XX Insulin in Subjects with Type 2 Diabetes Mellitus.

- A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of XXXX Administered in Combination with Metformin and XXX Compared with Metformin Plus XXX And Placebo and With Metformin Plus XXX And XXX In Subjects with Type 2 Diabetes Mellitus.

- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of XXXX Compared with Placebo in Subjects with Type 2 Diabetes Mellitus.

- A Randomized. Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of XXXX When Used in Combination with XXX With or Without Metformin in Subjects with Type 2 Diabetes Mellitus.

- A Randomized, Open-Label, Parallel-Group, Multicenter Study to determine Efficacy and Long-Term Safety of XXXX Compared with Insulin in Subjects with Type 2 Diabetes Mellitus.

- A Multi-Center, Randomized, Open Label, Active-Comparator Controlled Study to Assess the Efficacy, Safety and Tolerability Of XXXX(XXXX) Compared to XXX Patient with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin, Thiazolidinedione or Combination of Both.

- A Multi-Center, Randomized, Double Blind (Double Dummy), Active-Comparator Controlled Study to Compare the Efficacy, Safety and Tolerability of XXXX Versus XXX In Type 2 Diabetes Patients Inadequately Controlled with XXX Monotherapy or Metformin Plus XXX Combination Therapy.

- A Phase III, Randomized, Double-Blind, Placebo-And Active-Controlled, Multi-Center Study to Determine the Efficacy and Safety of XXXX In Subject with Type 2 Diabetes.

- A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial of GI Safety of XXXX Compared with Nonselective Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) In Osteoarthritis Patients.

- A Multi-Center, Randomized, Open-Label, Active Controlled, Parallel, Arm Study to Compare the Efficacy of 12 Weeks of Treatment with XXXX XX Mg, XXX To XXX As Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy in A Community-Based Practice Setting.

- An Open-Label Safety Study with Intermittent Use of XXX in Subjects with Lower Back Pain, Pain from Osteoarthritis of The Knee, Shoulder Pain, or Lateral Epicondylitis Pain

- A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Safety and Efficacy of XXXX In Subjects with Low Back Pain.

- A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Safety and Efficacy of XXXX In Subjects with Pain from Moderate Lateral Epicondylitis.

- A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Single Dose Comparison of The Analgesic Activity of XXXX And Placebo in Subjects with Shoulder Pain.

- Efficacy and Safety of Standard Titration XXXX Coupled with A Conventional Dietary Intervention

Or Intensive Dietary Intervention Versus a Standard Titration Algorithm, Alone in Patients with Type 2 Diabetes Initiating XXXX Mixed XX/XX Therapy

- Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia (BPH): BPH Registry and Patient Survey.
- An International Prospective Observational Registry in Subjects at Risk of Atherothrombotic Events.
- Phase II, A Study on Efficacy and Safety of XXX in the treatment of patients with Obesity.
- Phase III, A Safety and Efficacy Study of XXXX to Evaluate the Long-Term Treatment of Obesity in Adults with Obesity-Related Co-Morbid Conditions.
- An International Phase III, Randomized, Double-Blind, Placebo- and Active (XXX)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of XXX in Patients with Symptoms of Overactive Bladder
- An International Phase III, Randomized, Double-Blind, Active (XXX)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of XXX in Patients with Symptoms of Overactive Bladder
- Testosterone Replacement therapy for Assessment of long-Term Vascular Events and efficacy Response in hypogonadal Men (XXXXX) Study Phase: IV
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of XXXXX Xg Extended-Release Granules (XXXXX) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic XXXXX Ointment
- A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of XXXXXX to XXXXXX in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
- A randomized, sham controlled, double-blind, multi-center study of XXXXX XXXXX XXXXX (XXXX) as an Adjunctive Therapy for Knee Pain Relief and Improving Functional Outcomes in Knee Osteoarthritis (OA) Patients
- A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group, Placebo and Active Comparator-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of XXXXXX in Gout Patients with Hyperuricemia
- A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral XXXX in Mild to Moderate Ulcerative Colitis
- A Double-Blind, Placebo-Controlled, Phase II, Responsive Adaptive Randomization Study of XXXX in Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)

- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of XXXX Administered Orally to Children, Ages 6 to 17 Years, With Functional Constipation (FC)

- Open-Label Extension Study to Evaluate the Long-Term Safety of XXXXX Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric and Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment

- A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of XXXX for the Management of Hyperkalemia in Subjects Receiving XXXXX-XXXXX (XXXXX) Medications for the Treatment of Heart Failure (XXXXX)

- A Phase II Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses Of XXXX™ In Adult Subjects with Irritable Bowel Syndrome (IBS) Subtypes IBS-C And IBS-D

- Assessment of Efficacy and Safety of XXX-XXX for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment

- An observational study to compare human saliva samples to nasopharyngeal swab specimens for COVID-19 detection

- A Phase III double-blind placebo-controlled efficacy trial of XXXXXX vaginal gel for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection

- A population based epidemiological XXXXX/XXXX registry and research project

- A randomized, controlled pragmatic Phase IIIB/IV study of XXXX in patients with rheumatoid arthritis

- A 52-week, Phase III double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of pf-xxxxxx in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events

- A randomized, multicenter open label trial comparing the effectiveness of an "inclisirian first" implementation strategy to LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (>_70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION- INITIATE)

- A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus

- A multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study, Comparing RUXOLITINIB TOPICAL CREAM 1.5% (TARO PHARMACEUTICALS U.S.A., INC.) to OPZELURA TM (RUXOLITINIB) CREAM and both active treatments to a Placebo control in the treatment of Mild-To-Moderate Atopic Dermatitis

- An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, And Tolerability of Lorundrostat in Subjects with Uncontrolled Hypertension

- Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Medication Regimen

- A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study To Evaluate the Efficacy and Safety of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Medication Regimen

- A Phase 3b, open-label, single-arm study in adolescent and adult female participants to evaluate clinical symptom improvement and the safety of gepotidacin during treatment of uncomplicated urinary tract infections (acute cystitis)

- "STOP-CANCER" - Strategic Targeting for Optimal Prevention of Cancer

- A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-Part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-KHK in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-KHK in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

- A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

- A Randomized, Double-Blind, Active and Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

- A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-2 I9, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus

- 219685 - A seamless Phase 1/2, observer-blind, randomized, placebo-controlled, multicenter study to assess the safety and immunogenicity of a UTI vaccine when administered to adults 18 through 64 years of age and clinical efficacy when administered to females 18 through 64 years of age.

- Clinical evaluation of Phase Scientifics INDICAID COVID-19/FLU A&B Rapid Antigen Self-Test and the INDICAID COVID-19/FLU A&B Rapid Antigen test